With sales of specialty supplements expected to soar for the next five years, the suppliers of those products that are most prepared for regulation will garner the most benefit, according to analyst firm Business Insights.
Business Insights says companies that follow Good Manufacturing Practices (GMPs) and back their products with clinical research will have a significant advantage in the dietary supplements marketplace — a sector that draws more than 150 million U.S. consumers and could be worth $6 billion by 2011, according to nutraingredients.com.
Enzymes, Inc., follows current GMPs and other practices that ensure the highest levels of safety and quality. The company’s products are formulated by doctors and backed by more than 75 years of research and clinical use. The German Commission E and the Natural Medicines Database recognize its herbal extracts as safe and effective.